GLP-1 Receptors Agonists in Type 2 DiabetesMechanistic Insights and Evolving Treatment Options
Raghavan S, et al. J Am Heart Assoc. 2019;8(4):e011295.
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus.
Zelniker TA, et al. Circulation. 2019;139(17):2022–2031.
Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD [European Foundation for the Study of Diabetes] Study Group.
Schnell O, et al. Cardiovasc Diabetol. 2019;18(1):30.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial.
Gerstein HC, et al. Lancet. 2019;394(10193):121-130.
Husain M, et al. N Engl J Med. 2019; 381(9):841-851.
54-OR: oral semaglutide vs. empagliflozin added on to metformin monotherapy in uncontrolled type 2 diabetes: PIONEER 2.
Montanya E, et al. Diabetes. 2019;68(suppl 1):54-OR.
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Pratley R, et al. Lancet. 2019;394(10192):39-50.
A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes
Romera I, et al. Diabetes Ther. 2019;10(1):5-19.
Mechanistic Insights and Evolving Treatment Options
Mechanism-Based Strategies to Achieve Patient-Centered Care
Patient-Centered Management of Hyperglycemia in Primary Care
Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens
Translating Research Into Practice
Translating Reseach Into Practice
Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Discussions and Debates Around GLP-1 Receptor Agonists
Evolving Roles of GLP-1 Receptor Agonists
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Individualizing Evidence-Based Care
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Best Practices in Diagnosis and Management
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Consensus and Controversies Around Intensifying Noninsulin Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCP’s Role in Timely Recognition and Referral
An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies
Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management
Evolving Roles of GLP-1 Receptor Agonists
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Looking Beyond Hemoglobin A1c
Improving Patient Outcomes Through Shared Clinical Decision Making
What You Need to Know
Clinical Resource Center
Implications for PCSK9 Inhibitors in Clinical Practice
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
What the Pharmacist Needs to Know about PrEP
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors